Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 390

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 390
---
 by our laboratory, analytic, and business practices. For instance, significant elements of our genetic tests and testing procedures, including aspects of specimen preparation, bioinformatics algorithms, and related processes and adaptive learning software, are based on unpatented trade secrets and know -how. We expect to take steps to keep these trade secrets and know -howconfidential, such as entering into nondisclosure and confidentiality agreements with parties who have access to them, such as our employees and certain third parties, and entering into invention assignment agreements with our employees and consultants that require them to transfer any inventions developed in the course of their work to us. Patents We do not currently have any patents or patent applications directed to the sequences of specific genes or variants of such genes, nor do we rely on any such in -licensedpatent rights of any third party. To date, we have not developed any patentable products. Copyrights Heritas Argentina copyright is registered in Argentina, Paraguay, Mexico, Dominican Republic, Costa Rica and Panama. The Rewell copyright is registered in Argentina, Mexico, Peru, Chile and Colombia. Services Agreements CIBIC Pursuant to the Commercialization Agreement, we appointed CIBIC, one of our indirect shareholders, as exclusive agent for the commercialization of Heritas Diagnostics tests in Argentina. CIBIC cannot commercialize outside of Argentina without Heritas Argentina’s consent. The Commercialization Agreement’s term is 30 years, which 196 shall be automatically renewed for ten additional years at its term. In addition, CIBIC is not entitled to any of our intellectual property rights, trade secrets, or know -howassociated with the NGS tests. We grant CIBIC an exclusive, royalty -freelicense to use the Heritas brand for marketing NGS tests. Pursuant to the Commercialization Agreement, we, through Heritas Argentina, sell NGS tests to CIBIC at a price determined by pre -agreedpricing lists, after which CIBIC resells these NGS tests to its clients. Further, in accordance with the Commercialization Agreement, Heritas Argentina may update the NGS tests pricing lists at its discretion following five business days’ written notice to CIBIC. Heritas Argentina invoices CIBIC for NGS tests monthly. Pursuant to the Commercialization Agreement, CIBIC is authorized to supply the requisite reagents and equipment according to the specifications and requirements of Heritas Argentina. Additionally, CIBIC is responsible for covering the maintenance expenses of the equipment used in connection with